Asensus Surgical Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center
27 September 2021 - 12:55PM
Business Wire
Loginov Moscow is the first Russian hospital to initiate a
Senhance Surgical System program
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced that Loginov Moscow Clinical Scientific Center,
located in Moscow, Russia, has initiated its Senhance® Robotic
Surgery program following the purchase of a Senhance Surgical
System. The installation represents the first Senhance Surgical
System to be used within Russia.
“We are thrilled to be partnering with such an innovative,
forward-thinking institution for our first Senhance program within
Russia,” said Anthony Fernando, Asensus Surgical President and CEO.
“We share a commitment to advancing patient outcomes through the
use of new minimally invasive technologies and look forward to
helping Loginov expand their offerings to patients.’’
Asensus Surgical's technology platform, Senhance Surgical
System, is the first of its kind digital laparoscopic platform that
leverages augmented intelligence to provide unmatched performance
and patient outcomes through machine learning. Senhance goes beyond
the typical surgical robotic systems, providing surgical assurance
through haptic feedback, eye-tracking camera control, and 3D
visualization, and is the first platform to offer 3 mm instruments
(the smallest instrument available in the world on a robotic
surgical platform). The Senhance Surgical System is powered by the
Intelligent Surgical Unit™ (ISU™). The ISU enables machine
vision-driven control of the camera for a surgeon by responding to
commands and recognizing certain objects and locations in the
surgical field, and allows a surgeon to change the visualized field
of view using the movement of their instruments. The newest ISU
features expand upon these capabilities and introduce more advanced
features including: 3D measurement, digital tagging, image
enhancement, and enhanced camera control based on real-time data
from anatomical structures while performing surgery.
“Our team has been successfully and for many years developing
minimally invasive surgical technologies that help our patients
fast-track a return to an active life while preserving an optimal
therapeutic approach. We are ready to utilize the Senhance Surgical
System as part of our therapeutic options and hope that its use
will allow us to achieve even safer and more reproducible surgery
outcomes and ensure that a higher number of patients enjoy
favorable effects of minimal invasive surgery," said Professor Igor
Khatkov, Head of the Loginov Moscow Clinical Scientific Center.
About Loginov Moscow Clinical Scientific Center
The Loginov Moscow Clinical Scientific Center (The Loginov MCSC)
is one of the largest and most innovative institutions funded by
the Moscow Health Department. The Loginov MCSC is a
multi-disciplinary clinical, research, and training center hosting
48 medical departments, employing around 500 doctors, and
performing more than 13,000 annual operations. The Loginov MCSC is
headed by Professor Igor Khatkov, a proponent of minimally invasive
surgical technologies and a world leader in laparoscopic pancreatic
surgery. Since its founding in July 2013, The Loginov MCSC has
spent considerable resources on educational activities. The
training center trains specialists in 12 medical specialties in
residency and four specialties in fellowship. The center features a
program for the development of robotic surgery, headed by Professor
Nikolay Matveev, carried out in cooperation with the Department of
Surgery of the Biomedical Faculty, Pirogov Russian National
Research Medical University. To learn more please visit:
https://mknc.ru/.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit (ISU) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and The Loginov Moscow Clinical Scientific Center
hospital initiating a program with the Senhance System. These
statements and other statements regarding our future plans and
goals constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether the
Senhance Surgical System will help Loginov Moscow Clinical
Scientific Center expand their minimally invasive offerings to
patients and whether the use of the Senhance Surgical System will
allow Loginov Moscow Clinical Scientific Center to achieve even
safer and more reproducible surgery outcomes and ensure that a
higher number of patients enjoy favorable effects of minimal
invasive surgery. For a discussion of the risks and uncertainties
associated with the Company’s business, please review our filings
with the Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-K for the year ended December 31, 2020,
filed with the SEC on March 11, 2021 and our other filings we make
with the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the origination date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210927005065/en/
INVESTOR CONTACT: Mark Klausner or Mike Vallie,
443-213-0499 invest@asensus.com or MEDIA CONTACT: Kristin
Schaeffer, 858-354-8850 CG Life kschaeffer@cglife.com
Asensus Surgical, Inc. (NYSE:ASXC)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Asensus Surgical, Inc. (NYSE:ASXC)
Historical Stock Chart
Von Apr 2023 bis Apr 2024